Tumor necrosis factor superfamily co-stimulatory molecule (TNFSF/TNFRSF co-stimulators)

The Tumor necrosis factor (TNF) superfamily co-stimulatory molecules are a group of type I or type II transmembrane proteins that provide critical secondary signals for the activation, survival, and differentiation of immune cells, particularly T lymphocytes (Croft, M., Nature Reviews Immunology, 2009). Key members of this group include 4-1BB (CD137), OX40 (CD134), GITR, CD27, and CD40, which interact with their respective ligands to recruit TNF receptor-associated factors (TRAFs) and initiate downstream signaling pathways like NF-κB and MAPK (Ward-Kavanagh et al., Immunity, 2016). In oncology, these molecules are targeted by agonistic monoclonal antibodies to enhance anti-tumor T-cell responses and overcome immunosuppression within the tumor microenvironment (Sanmamed et al., Seminars in Oncology, 2015). Conversely, antagonistic approaches are explored for treating autoimmune and inflammatory disorders where these pathways are overactive. Despite their therapeutic potential, clinical development has been hampered by significant safety concerns, most notably the dose-limiting hepatotoxicity observed with 4-1BB agonists like urelumab (Segal et al., Clinical Cancer Research, 2017). Current research focuses on developing bispecific antibodies and localized delivery systems to improve the therapeutic index of these potent immune modulators (Buchan et al., Blood, 2018).

Other names

TNFRSF membersCo-stimulatory TNF receptorsTNF receptor superfamilyImmune checkpoint stimulators

Agonism of co-stimulatory receptors to enhance T-cell effector function and survival; Antagonism to inhibit immune-mediated inflammation (Croft, M., Nature Reviews Immunology, 2009).